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Key messages
What is already known about this subject?
 ► Patients with spondyloarthritis with 
radiographic sacroiliitis can be classified using 
the modified New York (mNY) criteria for 
ankylosing spondylitis (AS) or the Assessment of 
SpondyloArthritis international Society (ASAS) 
criteria for radiographic axial spondyloarthritis 
(r-axSpA). However, discussion remains whether 
these criteria define the same patients.
What does this study add?
 ► This study demonstrates that patients 
with axSpA classified as AS according to 
the mNY criteria and those classified as 
r-axSpA according to the ASAS criteria are 
mostly the same. These findings support the 
interchangeable use of the terms r-axSpA and 
AS.
How might this impact on clinical practice or 
future developments?
 ► Acknowledging that r-axSpA and AS are 
interchangeable increases comparability 
between studies, since both terms describe the 
same patients (ie, patients with axSpA with 
radiographic sacroiliitis). This also ensures that 
results from older research on AS cohorts can be 
directly compared with more recently published 
articles on r-axSpA cohorts.
AbSTrACT
background Patients with spondyloarthritis with 
radiographic sacroiliitis are traditionally classified 
according to the modified new York (mnY) criteria 
as ankylosing spondylitis (as) and more recently 
according to the assessment of spondyloarthritis 
international society (asas) criteria as radiographic axial 
spondyloarthritis (r-axspa).
Objective To investigate the agreement between the 
mnY criteria for as and the asas criteria for r-axspa and 
reasons for disagreement.
Methods Patients with back pain ≥3 months 
diagnosed as axspa with radiographic sacroiliitis 
(mnY radiographic criterion) were selected from eight 
cohorts (asas, esperanza, GesPiC, Oasis,  Reuma. pt, 
sCQM, sPaCe, UCsF). subsequently, we calculated the 
percentage of patients who fulfilled the asas r-axspa 
criteria within the group of patients who fulfilled the 
mnY criteria and vice versa in six cohorts with complete 
information.
results Of the 3882 patients fulfilling the mnY criteria, 
93% also fulfilled the asas r-axspa criteria. inversely, 
of the 3434 patients fulfilling the asas r-axspa criteria, 
96% also fulfilled the mnY criteria. The main cause 
for discrepancy between the two criteria sets was the 
reported age at onset of back pain.
Conclusion almost all patients with axspa with 
radiographic sacroiliitis fulfil both asas and mnY criteria, 
which supports the interchangeable use of the terms as 
and r-axspa.
bACKgrOund
Traditionally, patients with axial spondyloarthritis 
(axSpA) with definite structural changes on conven-
tional radiographs are classified according to the 
modified New York (mNY) criteria as ankylosing 
spondylitis (AS). However, they may also be clas-
sified according to the more recent Assessment of 
SpondyloArthritis international Society (ASAS) 
axSpA criteria as radiographic axSpA (r-axSpA).
Both the mNY and the ASAS axSpA classification 
criteria use the radiographic criterion as defined by the 
mNY criteria (ie, sacroiliitis of at least grade 2 bilater-
ally or at least grade 3 unilaterally). However, the addi-
tionally required (clinical) features of the classification 
criteria differ (table 1). Importantly, patients with 
age at onset of back pain ≥45 years cannot fulfil the 
ASAS criteria, but there is no age limit for the mNY 
criteria.1 2 Patients without the inflammatory character 
of back pain fulfil the ASAS criteria if another SpA 
feature is present, but only fulfil the mNY criteria if 
there is limitation in spinal mobility. These differences 
in the clinical part of both criteria sets raise the ques-
tion whether the two sets classify the same patients 
with axSpA with radiographic sacroiliitis.
The aim of this study was to investigate if patients 
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Table 1 Classification of axSpA with radiographic sacroiliitis using 
the mNY criteria for the classification of AS17 and the ASAS criteria for 
the classification of r-axSpA1
mnY criteria
for the classification of AS
ASAS criteria
for the classification of radiographic 
axSpA
1. Low back pain and stiffness for at least 
3 months, which improves with exercise 
and is not relieved by rest
2. Limitation of lumbar spine motion in 
the sagittal and frontal planes
3. Decreased chest expansion compared 
with age-matched and sex-matched 
controls
4a. Unilateral sacroiliitis grade 3 or 4
4b. Bilateral sacroiliitis grade 2 to 4
1. Back pain ≥3 months
2. Age at onset <45 years
3. Definite radiographic sacroiliitis 
according to mNY criteria
4. ≥1 SpA feature
 







 ► Good response to NSAIDs
 ► Family history for SpA
 ► HLA-B27 positive
 ► Elevated CRP (or ESR)
Definite AS if sacroiliitis as described in 
4a or 4b and any of the clinical symptoms 
(1–3)
Definite r-axSpA if fulfilment of 1 and 
2, sacroiliitis as described in 3 and at 
least one of the clinical SpA features as 
described in 4
AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis international 
Society; axSpA, axial Spondyloarthritis; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; HLA-B27, human leucocyte antigen B27; mNY, modified New 
York; NSAID, non-steroidal anti-inflammatory drugs;r-axSpA, radiographic axial 
spondyloarthritis.
criteria for r-axSpA and vice versa. The second objective was to 
investigate reasons for disagreement.
MeTHOdS
Patients diagnosed with axSpA who had back pain for at 
least 3 months and definite radiographic sacroiliitis based 
on local reading, according the mNY radiographic crite-
rion (#4a or 4b in table 1) were selected from eight cohorts 
(ASAS, Esperanza, GErman SPondyloarthritis Inception 
Cohort (GESPIC), Outcome in Ankylosing Spondylitis Inter-
national Study (OASIS),  Reuma. pt, Swiss Clinical Quality 
Management (SCQM), SPondyloArthritis Caught Early cohort 
(SPACE) and University of California San Francisco (UCSF) 
axSpA cohort1 3–9). The ASAS cohort included patients with 
undiagnosed axSpA irrespective of symptom duration in 25 
ASAS centres across 16 countries in Western Europe, Turkey, 
Asia, Colombia and Canada between 2005 and 2009.1 Espe-
ranza is a Spanish national health programme for early SpA, 
which started inclusion in 2007.6 GESPIC started in 2000 
and consists of patients with axSpA and symptom duration 
of up to 10 years.7 OASIS consists of Dutch, Belgian and 
French patients with established AS, which started in 1996.8 
Since 2008,  Reuma. pt started with the inclusion of Portuguese 
rheumatic patients of various diseases and disease stages in a 
national register, including patients with early and established 
axSpA.3 The SCQM axSpA cohort started in Switzerland in 
2005 including patients with early and established disease.4 
SPACE is an early chronic back pain cohort including Euro-
pean patients since 2009.9 Patients in the UCSF axSpA cohort 
started enrolling in 2007; patients with early and established 
disease from the UCSF clinic are included.5 Approval from the 
medical ethical committees was obtained per cohort, and for 
all patients written informed consent was obtained prior to 
inclusion.
For these cohorts, we calculated how many patients with 
SpA with radiographic sacroiliitis fulfil the mNY criteria 
(mNY+) and the ASAS r-axSpA criteria (ASAS+). Subse-
quently, we calculated the percentage of patients who fulfil 
the ASAS r-axSpA criteria within the group of patients who 
fulfil the mNY criteria. In six cohorts, we were also able to 
calculate the percentage of patients fulfilling the mNY criteria 
within the group fulfilling the ASAS r-axSpA criteria. For the 
Esperanza and OASIS cohorts, specific information on the 
individual items of the mNY clinical criteria was unavailable. 
Consequently, it was not possible to calculate the percentage 
of patients fulfilling the mNY criteria within the subgroup 
fulfilling the ASAS criteria. Flowcharts were used to visualise 
fulfilment of the criteria sets (online supplementary figure S1).
For the patients with axSpA with radiographic sacroiliitis, the first 
step was to determine whether a patient had inflammatory back 
pain (IBP). For the purpose of this study, the first clinical criterion 
of the mNY was equated to IBP according to the ASAS definition.10 
The second step was to determine the number of SpA features (<1 
vs ≥1) as well as whether the patient had mobility restrictions. 
Mobility restrictions were defined using the age-adjusted fifth 
percentile scores of healthy individuals from Ramiro et al11; if the 
Schober’s test and lateral spinal flexion were below the age-adjusted 
fifth percentile value or chest expansion was below the age-adjusted 
and height-adjusted fifth percentile value, mobility was considered 
restricted. The final step was to look at age at onset of back pain 
(<45 vs ≥45 years old).
reSulTS
A total of 7636 patients with a SpA diagnosis and back pain 
>3 months were included in these eight cohorts. Of these, 4041 
patients had a diagnosis of axSpA with radiographic sacroiliitis 
and were available for analysis. In total, 3882 patients fulfilled 
the mNY criteria, of which 3607 (93%; range 88%–100%) also 
fulfilled the ASAS r-axSpA criteria (figure 1A). From the six 
cohorts (N=3721) in which the fulfilment of the mNY criteria 
in the subgroup of patients fulfilling the ASAS r-axSpA criteria 
(N=3434) could be analysed, 3300 (96%; range 84%–98%) 
also fulfilled the mNY criteria (figure 1B).
For all 4041 patients with r-axSpA fulfilment of the criteria 
sets was determined (online supplementary tables S1-S3). In 
total, 3607 (89%) of patients fulfilled both criteria sets; 275 
(7%) only the mNY criteria; 134 (3%) only the ASAS criteria 
and 25 (1%) neither set (table 2).
The main difference between the two criteria sets was 
caused by the reported age at onset of back pain; 99.7% of the 
patients fulfilling the mNY criteria could potentially fulfil the 
ASAS criteria except for registered age at onset (online supple-
mentary figure S4).
Out of the 275 mNY+patients not fulfilling the ASAS criteria 
(7% of all included patients), 265 (96%) cases were due to the 
age criterion and 10 (4%) due to the absence of SpA features 
including IBP (online supplementary table 1). These 10 patients 
had spinal mobility limitation as the only clinical feature. The 
134 mNY-/ASAS+ did not have mobility restriction or IBP but 
another SpA feature instead. For the cohorts that had data avail-
able (N=1833), the human leucocyte antigen B27 (HLA-B27) 
status was determined in each of the subgroups. In the mNY+/
ASAS+ group, HLA-B27 positivity was 68%. In the mNY-/
ASAS+ group, a similar percentage was found (72%), whereas 
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Figure 1 Percentage of patients fulfilling ASAS r-axSpA within 
subgroup fulfilling mNY criteria (3607/3882) (A) and percentage 
of patients fulfilling mNY criteria within subgroup fulfilling ASAS 
r-axSpA (3300/3434) (B), per cohort and overall. ASAS, Assessment 
of SpondyloArthritis international Society cohort; Esperanza, 
Spanish national health programme for early SpA; GESPIC, GErman 
SPondyloarthritis Inception Cohort; mNY, modified New York; OASIS, 
Outcome in Ankylosing Spondylitis International Study; r-axSpA, 
radiographic axial spondyloarthritis; Reuma.pt, Portuguese Register for 
Rheumatic Diseases; SCQM, Swiss Clinical Quality Management cohort; 
SPACE, SPondyloArthritis Caught Early cohort; UCSF, University of 
California San Francisco axSpA cohort.
Table 2 Percentage of patients with axSpA with radiographic sacroiliitis fulfilling both sets of criteria, either criteria set or neither
mnY+ASAS+ mnY+ASAS- mnY- ASAS+ mnY- ASAS- Total mnY+* Total ASAS+†
ASAS (N=114) 86% (98) 2% (3) 10% (11) 2% (2) 89% (101) 96% (109)
GESPIC (N=96) 81% (78) 12% (11) 6% (6) 1% (1) 93% (89) 88% (84)
Esperanza (N=109) 97% (106) 3% (3) NA‡ NA‡ 100% (109) –
OASIS (N=211) 95% (201) 5% (10) NA‡ NA‡ 100% (211) –
Reuma.pt (N=1320) 88% (1156) 7% (93) 4% (55) 1% (16) 95% (1249) 92% (1211)
SCQM (N=1806) 89% (1612) 8% (148) 2% (40) 0.3% (6) 97% (1760) 91% (1652)
SPACE (N=92) 84% (77) 0% (0) 16% (15) 0% (0) 84% (77) 100% (92)
UCSF (N=293) 95% (279) 2.5% (7) 2.5% (7) 0% (0) 98% (286) 98% (286)
Total (N=4041) 89% (3607) 7% (275) 3% (134) 1% (25) 96% (3882)   –
*The total percentage of patients who fulfil the mNY criteria per cohort and in total.
†The total percentage of patients who fulfil the ASAS r-axSpA criteria per cohort and in total.
‡Specific information on the individual items of the mNY clinical criteria was unavailable, it was therefore not possible to accurately calculate the number of patients fulfilling 
the mNY in the subgroup fulfilling the ASAS r-axSpA criteria.
ASAS, Assessment of SpondyloArthritis international Society cohort; Esperanza, Spanish national health programme for early SpA; GESPIC, GErman SPondyloarthritis Inception 
Cohort; NA, not available; OASIS, Outcome in Ankylosing Spondylitis International Study; Reuma.pt, Portuguese Register for Rheumatic Diseases; SCQM, Swiss Clinical Quality 
Managementcohort; SPACE, SPondyloArthritis Caught Early cohort; UCSF, University of California San Francisco axSpA cohort; axSpA, axial spondyloarthritis; mNY, modified New 
York; r-axSpA, radiographic axial spondyloarthritis.
only slightly higher than the mNY-/ASAS- group (42%) (online 
supplementary table S2).
diSCuSSiOn
‘Classification criteria are standardised definitions that are 
primarily intended to create well-defined, relatively homo-
geneous cohorts of patients for clinical research; they are not 
intended to capture every single patient but rather to capture the 
majority of patients who share key features of the condition’.12 
Patients with axSpA with radiographic sacroiliitis are tradition-
ally classified according to the mNY criteria and more recently 
according to the ASAS criteria. The data presented in this study 
show that patients with axSpA classified as AS according to mNY 
criteria and those classified as r-axSpA according to ASAS criteria 
are mostly the same. Nonetheless, there is minor disagreement, 
mainly due to age at onset of back pain. The latter is reported 
by patients at the time of diagnosis in almost all cohorts and 
therefore susceptible to recall bias, a valid concern especially 
for the cohorts containing patients with a long disease duration 
and long gap between symptom onset and diagnosis. The age 
criterion was introduced with the implementation of the ASAS 
criteria in 2009; this was mainly based on data from Feldtkeller 
et al,13 which showed that 95% of AS patients reported an age 
of onset <45 years. Based on this fact, one would expect around 
5% of the patients fulfilling the mNY criteria not to fulfil the 
ASAS criteria. In this study, this percentage is 7%.
Due to the nature of the data and the slight differences 
between the two criteria sets some assumptions had to be made, 
which is a limitation to this study. The first assumption concerns 
IBP; in general, the ASAS definition of IBP10 was used. However, 
if this was unavailable (and could not be defined from indi-
vidual components of IBP), the rheumatologist’s assessment as 
provided in the dataset was used instead. The second assump-
tion regards mobility limitations; according to the mNY criteria, 
mobility limitations are to be identified based on age-adjusted 
and gender-adjusted comparisons; however, in the original 
publication no reference values were provided. Therefore, refer-
ence values resulting from the MOBILITY study11 were used. If 
information on mobility was unavailable, the rheumatologist’s 
judgement of ‘restricted mobility’ as provided in the dataset was 
used. Both assumptions may have influenced the proportion of 
patients fulfilling either of the criteria sets.
As shown in the HLA-B27 analysis, the mNY+/ASAS- group 
showed a lower percentage of HLA-B27 positives. HLA-B27 
positivity is associated with earlier disease onset,13–15 which may 
explain the low percentage of HLA-B27+ in the mNY+/ASAS- 
group (48%) and is in line with the highest HLA-B27 positivity 
(72%) in the mNY-/ASAS+ group. An alternative explanation 
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as having r-axSpA as a higher HLA-B27 percentage is expected 
in mNY+ patients. The overall percentage of HLA-B27 found 
in this study is relatively low, which may be due to the local 
readings of the radiographs that may have resulted in false clas-
sifications for both classification sets.16
In conclusion, this study found that agreement between the mNY 
and ASAS r-axSpA criteria is very high, which supports the inter-
changeable use of the terms AS and r-axSpA. This has important 
implications for the axSpA research field, since older literature 
used mNY and AS, whereas more recent literature often uses ASAS 
criteria and r-axSpA. Acknowledging that both criteria sets identify 
the same patients implies that older literature on AS and newer liter-
ature on r-axSpA can be directly compared.
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